Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Generic Alfuzosin vs Xatral® XL in Healthy Thai Males
NCT06316336Phase 1Not yet recruiting
- Sponsor
- Pharma Nueva
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of alfuzosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Pharma Nueva. Primary endpoints: Plasma Area Under the Curve (Day 6 and Day 7) and Peak Plasma Concentration (Day 6 and Day 7). Planned start Jun 2024; status: not yet recruiting.
02
Drugs
alfuzosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT06316336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316336.